

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, a consultee noted that young drug abusers, recent immigrants and asylum seeker children should be considered in this appraisal. However, NICE does not exclude any specific groups of children and young people in this appraisal. Therefore, this is not viewed as an equality issue.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the draft scope relating to equality.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director: Elisabeth George

Date: 31st May 2012